We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Results Confirm Effectiveness of Echotherapy for Breast Fibroadenoma

By MedImaging International staff writers
Posted on 21 Jun 2016
Print article
Image: The Ecopulse medical device for the treatment of BFAs and benign thyroid nodules (Photo courtesy of Theraclion).
Image: The Ecopulse medical device for the treatment of BFAs and benign thyroid nodules (Photo courtesy of Theraclion).
A French therapeutic ultrasound company has announced the results of a German trial of its ecotherapy technology that have confirmed its effectiveness in the destruction of Breast FibroAdenoma nodules.

The results of the Breast FibroAdenoma (BFA) trial in which 27 patients were enrolled, were presented at the German Congress of Senology in Dresden, Germany, at the end of May 2016. The aim of the study was to evaluate the safety and efficacy of the new technique.

The trial took place at Tübingen University (Tübingen, Germany). The researchers used therapeutic ultrasound technology developed by Theraclion (Malakoff, France).

Biopsies were performed 12 months after the ecotherapy procedure and showed that nearly 24 of the 27 patients (nearly 90%) had no residual vital BFA tissue. All the patients except for one were prepared to recommend the procedure. The original aim of the non-invasive BFA treatment was to reduce the volume of BFAs, however the new trial confirmed that complete tissue destruction was also possible. The procedure does not using ionizing radiation, and could be used to treat breast cancer patients in the near future.

CMO of Theraclion, Michel Nuta, said, “These results are extremely encouraging. Echotherapy has initially been designed for volume reduction of a nodule, not for its complete destruction. These preliminary results show that there is reason to believe that by adapting the protocol, complete tissue destruction can be obtained.”

Related Links:
Tübingen University
Theraclion
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Table
Powered Ultrasound Table-Flat Top
New
Color Doppler Ultrasound System
KC20
New
Enterprise Imaging & Reporting Solution
Syngo Carbon

Print article

Channels

Nuclear Medicine

view channel
Image: Whole-body maximum-intensity projections over time after [68Ga]Ga-DPI-4452 administration (Photo courtesy of SNMMI)

New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients

Clear cell renal cell cancer (ccRCC) represents 70-80% of renal cell carcinoma cases. While localized disease can be effectively treated with surgery and ablative therapies, one-third of patients either... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more